Business Wire

AKUR8

15.9.2022 15:01:42 CEST | Business Wire | Press release

Share
Akur8 Releases its first Global Insurance Pricing Survey, Revealing a Desire Across the Insurance Industry for Convergence Between Actuarial and Data Science

Akur8, the AI insurance pricing company, published today results from its first global pricing report, “Akur8 Global Pricing Survey: convergence between actuarial and data science awaited!”

Shedding new light on the pricing challenges and expectations of insurance carriers worldwide, Akur8’s new insurance survey offers key insights from over a hundred insurance pricing professionals across lines of business, representing 31 countries.

Among the findings of the survey, some key takeaways include:

  • For major insurance players, pricing is the most important competitive differentiator in the marketplace, with 81% of respondents ranking it as a very important criteria.
  • Pricing practices are still facing legacy challenges, among which the lack of data and resources are considered to be the biggest hurdles, along with the limitations of current IT and tools.
  • Established pricing processes and tools, though robust, continue to make use of legacy pricing approaches, having not yet activated the potential of pricing as a business lever.
    • Overall, pricing processes for non-life insurance companies remain mostly manual, leveraging GLMs with little variety in data sources.
    • Unlike technical models that are rarely updated more than once a year, commercial prices are revised several times a year without updated risk assessments.
    • Tools are not disruptive, with manual software still being the most represented. Excel continues to be used across many steps of the pricing process, including aspects related to predictive modeling.
  • In the future, pricing teams expect major untapped value potential to be delivered through automation and integrated tool suites.
    • Pricing teams have a major interest in measuring the ultimate business impact of ratemaking decisions, down to the combined ratio, yet they are limited in doing so.
    • Pricing teams across the insurance industry are committed to activating the power of data over the next few years to improve their business performance.
    • The highest value for insurance pricing will be realized through the convergence of data science and actuarial science.

"The introduction of this survey allows Akur8 to gather direct insights from insurance companies and underwriters across the globe, to better understand the industry's pricing practices, challenges and expectations for the future", declared Samuel Falmagne, co-founder and CEO of Akur8. "Through these findings, we are excited to provide the insurance industry with new thought leadership on pricing processes and practices, and to pave the way for next generation pricing tools and approaches.”

The full findings of the Akur8 Global Insurance Pricing Survey is available at www.akur8.com/white-papers/global-pricing-survey.

About Akur8

Akur8 is revolutionizing insurance pricing with Transparent Machine Learning, boosting insurers’ pricing capabilities with unprecedented speed and accuracy across the pricing process without compromising on auditability or control.

Our modular pricing platform automates technical and commercial premium modeling. It empowers insurers to compute adjusted and accurate rates in line with their business strategy while materially impacting their business and maintaining absolute control of the models created, as required by state regulators. With Akur8, time spent modeling is reduced by 10x, the models’ predictive power is increased by 10% and loss ratio improvement potential is boosted by 2-4%.

Akur8 already serves 50+ customers across 20+ countries, including AXA, Generali, Munich Re, Tokio Marine North America Services (TMNAS); specialty insurer Canopius and MGA Bass Underwriters; consulting partners Xceedance and Perr & Knight; and insurtechs Manypets and wefox. Over 700 actuaries use Akur8 daily to build their pricing models across all lines of business. Akur8’s strategic partnerships include Milliman, Guidewire, Duck Creek and Sapiens.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005588/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Oral‑B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability‑Focused Oral Health Studies13.5.2026 09:06:00 CEST | Press release

Oral‑B and iADH build on four years of action to advance inclusive oral care and whole‑body health41% of Europeans identify as living with a disability, representing a four‑point increase wave‑on‑wave Oral‑B today announces The Big Rethink 2026, the next evolution of its flagship oral health inclusion programme, developed in partnership with the International Association for Disability and Oral Health (iADH). The new phase introduces Project Steady, one of Europe’s largest real‑world studies exploring oral care experiences among people with disabilities, their carers and dental professionals. The programme aims to reduce everyday barriers to oral care through inclusive design, evidence-based research and professional education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511175864/en/ Oral B Announces The Big Rethink 2026, Launching One of Europe’s Largest Disability Focused Oral Health Studies Oral health for Whole-Bo

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results13.5.2026 08:38:00 CEST | Press release

FY2025 Pipeline Successes Set the Stage for Pivotal Product LaunchesAchieved Latest FY2025 Management GuidanceTakeda is Entering a New Era & Transforming for Growth Acceleration Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER). Core Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth. Reported Operating Profit increased by 19.3% YoY at AER, also reflecting a step-down in amo

Allianz Delivers Record Operating Profit in Strong Start to 202613.5.2026 07:20:00 CEST | Press release

1Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512320157/en/ Oliver Bäte, Chief Executive Officer of Allianz SETotal business volume at 53.0 billion euros, an internal growth of 3.5 percent1. This was driven by a strong development in Property-Casualty and Asset Management Operating profit rises 6.6 percent and reaches a record level of 4.5 billion euros Shareholders’ core net income advances by 48.4 percent to 3.8 billion euros, impacted by the sale of the stakes in our Indian Joint Ventures. Underlying growth, which adjusts for the sale effects and offsetting measures, is strong at 7 percent2Core earnings per share grow 50.7 percent and reach 9.96 euros. Adjusted for the above-mentioned effects, underlying growth is excellent at 9 percent 2Annualized core RoE at 24.2 percent, underlying level very strong at 18 percent 2Solvency IIratio3 increases by 2 percentage points to 221 percent4. Capital generation was str

Abu Dhabi's Phoenix Group Partners with DC Max to Unlock $8 Billion European AI Data Center Opportunity, with Lyon, France as First Deployment13.5.2026 07:00:00 CEST | Press release

18MW AI-ready facility developed in partnership with DC Max, a French data center developer with a 1GW pipeline Partnership provides preferential access to DC Max’s development pipeline, accelerating Phoenix’s goal towards an excess of 1GW global AI and HPC platform across Europe and the GCC Phoenix has already acquired the land for the Lyon site, which comes with secured permits, grid connection in place and available power, enabling construction to begin in July 2026, with delivery targeted between Q4 2027 and Q1 2028 Phoenix Group PLC (ADX: PHX), an IHC portfolio company and global digital infrastructure operator, today announced a strategic partnership with DC Max to develop its first European AI data center, an 18MW facility in Lyon, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512531777/en/ From left to right: Matthias Luecker, Chairman of DC Max, and Munaf Ali, Co-Founder and Group CEO of Phoenix Group, d

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca13.5.2026 07:00:00 CEST | Press release

Agreement includes license for Owkin’s AI Scientist, K Pro, for three years. As part of this license, Owkin will develop novel biopharma agents for AstraZeneca, usable through K Pro. This will include capabilities to quickly analyze and forecast the competitive landscape for specific pharmaceutical targets, assets, and trials. Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin’s AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the end-to-end development of AI agents to run on K Pro, integrated within AstraZeneca’s IT infrastructure and decision workflows. The new agents' functionality is intended to help AstraZeneca’s decision-making

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye